GENETIC TECHNOLOGIES ADR EACH REPR 30 SPONGENETIC TECHNOLOGIES ADR EACH REPR 30 SPONGENETIC TECHNOLOGIES ADR EACH REPR 30 SPON

GENETIC TECHNOLOGIES ADR EACH REPR 30 SPON

No trades
See on Supercharts

0A4N fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through the following segments: EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987, and is headquartered in Fitzroy, Australia.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0A4N does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company